Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.

Claire C J DekkersC David SjöströmPeter J GreasleyValerie CainDavid W BoultonHiddo J Lambers Heerspink

Published in: Diabetes, obesity & metabolism (2019)

ePV may be used as a proxy to assess changes in plasma volume during dapagliflozin treatment. Dapagliflozin consistently decreased ePV compared to placebo in a broad population of patients with type 2 diabetes.

Keyphrases

clinical trial
replacement therapy
study protocol
smoking cessation